NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.
about
Comparative Study of Activities of a Diverse Set of Antimycobacterial Agents against Mycobacterium tuberculosis and Mycobacterium ulceransNew Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development.In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.Mutant Alleles of lptD Increase the Permeability of Pseudomonas aeruginosa and Define Determinants of Intrinsic Resistance to Antibiotics.Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.Targeting bacterial topoisomerases: how to counter mechanisms of resistance.Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae.DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens.Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin against Escherichia coli in a Neutropenic Murine Thigh Infection Model.The Macromolecular Machines that Duplicate the Escherichia coli Chromosome as Targets for Drug Discovery.
P2860
Q28833171-FDBC8602-E4F4-4A33-9599-24D4720D7168Q36153263-A17267A9-F6CE-4BE8-9B05-F0F3FB5921EEQ36933417-98C07DBD-FCB4-4A33-AE64-76D02FE4AB1AQ38367630-4636036E-161F-4F8D-9DD0-41B257D3AE6FQ38797016-644F639C-F4F3-453D-8FDC-6156FDF35048Q38855273-462D5EAD-1ADB-47EB-A8DF-C788EAA64F92Q38949284-4669CE45-56A3-4C39-A1DE-AD973C935DF1Q38968355-8DBA33F1-E435-43F5-AA26-F0A6B2BA6EDBQ39030692-6B8273D7-6E8F-4D11-B433-FD130FE02D03Q39078552-7D60F181-E080-451D-87A0-865D78048D63Q40833065-6279A0C6-4285-455B-B33E-87AB41E42215Q41687386-8BB18B1A-5625-480C-95EB-F8A3ED8603EEQ50077307-4146EE2D-533E-453E-9A17-ED2407CE531CQ52656083-8C00298D-CCC4-4F5C-8E7C-CB93344A08CF
P2860
NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
NBTI 5463 is a novel bacterial ...... bacteria and in vivo efficacy.
@en
NBTI 5463 is a novel bacterial ...... bacteria and in vivo efficacy.
@nl
type
label
NBTI 5463 is a novel bacterial ...... bacteria and in vivo efficacy.
@en
NBTI 5463 is a novel bacterial ...... bacteria and in vivo efficacy.
@nl
prefLabel
NBTI 5463 is a novel bacterial ...... bacteria and in vivo efficacy.
@en
NBTI 5463 is a novel bacterial ...... bacteria and in vivo efficacy.
@nl
P2093
P2860
P356
P1476
NBTI 5463 is a novel bacterial ...... bacteria and in vivo efficacy.
@en
P2093
Asha Nayar
David E Ehmann
Folkert Reck
Gregory G Stone
Joseph V Newman
Mark Cronin
Michele Johnstone
Sussie Hopkins
Thomas J Dougherty
P2860
P304
P356
10.1128/AAC.02778-13
P407
P577
2014-02-24T00:00:00Z